Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Richard Pratley MD
Richard E. Pratley MD Associate Editor
Silvio Inzucchi MD
Silvio E. Inzucchi MD Editor-in-Chief
Kathleen Dungan MD, MPH
Kathleen M. Dungan MD, MPH Advisory Board
See All Experts
Published in Diabetes

News · July 09, 2023

ADA 2023: Semaglutide and Cagrilintide Combination Safe and Effective for Type 2 Diabetes

Participants saw significant reduction in HbA1c and weight following weekly doses of CagriSema versus monotherapy

PracticeUpdate Editorial Team

 

 Save  Recommend
 Share

Further Reading

Most Read This Week

Recently Updated